You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent

    SBC: PACDNA LLC            Topic: NCI

    Project Summary/Abstract Mutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeuticintervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a singlemutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitorshas heightened the importance of alternative methods targeting the o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects

    SBC: General Biophysics LLC            Topic: NIA

    PHASE II APPLICATION(STTR Program PAS-22-197) “Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects” ABSTRACTAlzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant role in the onset an ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons with Dementia

    SBC: HOPEFUL AGING LLC            Topic: R

    PROJECT SUMMARY/ABSTRACTHealthcare systems around the world, including within the United States, have long-established shortages of trained caregivers (WHO, 2016; Jones, Liu, Murfield, and Moyle, 2020). The American Health Care Association (2019) states that “the health care system has experienced a shortage of trained caregivers for critical roles for some time.” This scarcity directly impact ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes

    SBC: VALA SCIENCES, INC.            Topic: NHLBI

    Cardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy

    SBC: FILTRO MEDICAL INC.            Topic: 102

    PROJECT SUMMARYDosing of chemotherapeutics is limited by systemic toxic side effects. We are developing a new class of image- guided temporarily deployable, endovascular catheter-based medical devices that selectively remove specific drugs from the blood stream to reduce systemic toxicities. The proposed ChemoFilters incorporate specialized materials that bind target drugs in situ through a variet ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Targeting TLR4-lipid rafts to prevent postoperative pain

    SBC: RAFT PHARMACEUTICALS LLC            Topic: 108

    PROJECT SUMMARY Postoperative pain is a prevalent source of pain requiring appropriate management to reduce its impact upon quality of life. Even with the availability of several analgesics, postoperative pain is often undermedicated because of concern related to the adverse consequence of the available therapeutics (e.g., NSAIDs and opiates), including addiction and decreased survival of cancer p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Drug Delivery Platform as Medical Countermeasure for treatment of Gastrointestinal Radiation Damage

    SBC: THE TINY CARGO COMPANY            Topic: 102

    Project Summary/Abstract The Tiny Cargo Company offers a unique, orally administered medical countermeasure for treatment and prevention of the gastrointestinal (GI) side effects of cancer radiation therapy (RT). Our therapeutic is comprised of milk-derived extracellular vesicles (mEVs) loaded with a safe and highly effective radioprotective drug – a formulation that we call Milactatm. RT compli ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Novel probiotics to mitigate xenobiotic toxicity through microbial biotransformation

    SBC: NEXILICO, INC.            Topic: NIEHS

    PROJECT SUMMARY / ABSTRACT The human gut microbiome consists of trillions of microorganisms which metabolize a variety of xenobiotic compounds, including environmental chemicals, thereby affecting their overall toxicity to the host organism. Gut microorganisms can either increase or decrease the toxicity of xenobiotic compounds based on reactions with microbial enzymes, which is referred to as Mic ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Nanopore Array for Multiparameter Analysis of Single Extracellular Vesicles

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: NIGMS

    Project Summary Today, researchers and clinicians, in academia and industry, lack the tools and technologies needed to accurately characterize, differentiate, and sort extracellular vesicles (EVs); currently available technologies were simply not developed to characterize entities smaller than 200 nanometers in size. While the importance of EVs in directing cargo delivery for intercellular communi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Peripheral Artery Disease

    SBC: AGEX THERAPEUTICS INC            Topic: NHLBI

    ABSTRACT Peripheral artery disease (PAD) is associated with vascular obstructions in the extremities, leading to intermittent claudication, ischemic ulcers, leg pain at rest, and amputation. In the US, approximately 6.5 million people have peripheral artery disease (PAD), affecting 12-20% of people over 60 years of age . Current cell therapies to restore limb perfusion have shown only moderate ben ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government